Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 74

Sort by

Sort Order Select

Journal Articles

Cox Proportional Hazards Deep Neural Network Identifies Peripheral Blood Complete Remission (PB-CR) to be at Least Equivalent to Morphologic CR in Predicting Outcomes of Patients Treated with Azacitidine - a Prospective Cohort Study By the AGMT

Blood (2022) 140 (Supplement 1): 1346–1349.

https://doi.org/10.1182/blood-2022-168521

Published: 2022

Journal Articles

Delineating CDK9- Regulated Molecular Events for the Development of Rationally Derived Multiple Myeloma Treatment Strategies

Osman Aksoy, Klaus Podar, Sonia Vallet, Judith Lind, Vincent Sunder-Plassmann, Martin Pecherstorfer

Blood (2022) 140 (Supplement 1): 12478–12479.

https://doi.org/10.1182/blood-2022-169914

Published: 2022

Journal Articles

Combined Targeting of Distinct c-Myc and JunB Transcriptional Programs Inducing Synergistic Anti-Myeloma Activity

Judith Lind, Sonia Vallet, Karoline Kollmann, Osman Aksoy, Vincent Sunder-Plassmann, Fengjuan Fan, Elisabeth Zwickl-Traxler, Dagmar Stoiber, Latifa Bakiri, Erwin F Wagner, Martin Sattler, Martin Percherstorfer, Klaus Podar

Blood (2021) 138 (Supplement 1): 2644.

https://doi.org/10.1182/blood-2021-145001

Published: 2021

Journal Articles

Delineating CDK9 Regulated Molecular Events for the Development of Rationally Derived Multiple Myeloma Treatment Strategies

Osman Aksoy, Judith Lind, Vincent Sunder-Plassmann, Martin Percherstorfer, Sonia Vallet, Klaus Podar

Blood (2021) 138 (Supplement 1): 1598.

https://doi.org/10.1182/blood-2021-149254

Published: 2021

Journal Articles

Combined Targeting of Distinct c-Myc and JunB Transcriptional Programs for Multiple Myelioma Therapy

Judith Lind, PhD, Felix Czernilofsky, Sonia Vallet, MD, Fengjuan Fan, PhD, Martin Sattler, PhD, Latifa Bakiri, Erwin F Wagner, PhD, Martin Percherstorfer, MD, Klaus Podar, MD PhD

Blood (2019) 134 (Supplement_1): 4415.

https://doi.org/10.1182/blood-2019-125202

Published: 2019

Journal Articles

Multiple Myeloma Pathogenesis: The Role of Junb in Bone Marrow Angiogenesis

Blood (2019) 134 (Supplement_1): 4341.

https://doi.org/10.1182/blood-2019-128854

Published: 2019

Journal Articles

Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group

Blood (2019) 134 (Supplement_1): 3821.

https://doi.org/10.1182/blood-2019-128153

Published: 2019

Journal Articles

The Pathophysiologic Role of JunB in Multiple Myeloma Pathogenesis: Focus on Bone Marrow Angiogenesis

Stefano Malvestiti, Fengjuan Fan, PhD, Muhammad Hasan Bashari, MD, Eugenio Morelli, MD, Sonia Vallet, MD, Martin Sattler, PhD, Latifa Bakiri, PhD, Anja Seckinger, MD, Dirk Hose, MD, Hartmut Goldschmidt, MD, Inka Zörnig, PhD, Martin Pecherstorfer, MD, Erwin Wagner, PhD, Pierfrancesco Tassone, MD, Dirk Jäger, MD, Klaus Podar, MD MSc PhD

Blood (2016) 128 (22): 2091.

https://doi.org/10.1182/blood.V128.22.2091.2091

Published: 2016

Journal Articles

The AP-1 Transcription Factor JunB Promotes Multiple Myeloma (MM) Cell Proliferation, Survival and Drug Resistance in the Bone Marrow Microenvironment

Fengjuan Fan, PhD, Sonia Vallet, MD, Martin Sattler, PhD, Giovanni Tonon, MDPhD, Muhammad Hasan Bashari, Latifa Bakiri, PhD, Hartmut Goldschmidt, MD, Erwin F. Wagner, PhD, Dirk Jaeger, MD, Klaus Podar, MD PhD

Blood (2014) 124 (21): 3446.

https://doi.org/10.1182/blood.V124.21.3446.3446

Published: 2014

Journal Articles

Combinational Therapy of Lenalidomide with Activin A Neutralizing Antibody; Preclinical Rationale for a Novel Anti-Myeloma Strategy

Tyler Scullen, Sonia Vallet, Loredana Santo, Mariateresa Fulciniti, PhD, Homare Eda, Diana D. Cirstea, MD, Kishan Patel, Andrew Yee, Anuj Mahindra, MD, Noopur Raje, MD

Blood (2012) 120 (21): 1871.

https://doi.org/10.1182/blood.V120.21.1871.1871

Published: 2012

Journal Articles

Niche-Based Screening Identifies Novel Small Molecules That Overcome Stromal Effects in Multiple Myeloma

Blood (2012) 120 (21): 571.

https://doi.org/10.1182/blood.V120.21.571.571

Published: 2012

Journal Articles

Increased Sclerostin Secretion in Multiple Myeloma Plays a Central Role in Osteolytic Bone Disease

Homare Eda, Loredana Santo, Diana Cirstea, Andrew J. Yee, Anuj Mahindra, Tyler Scullen, Neeharika Nemani, Yuko Mishima, Sonia Vallet, Noopur Raje

Blood (2012) 120 (21): 3989.

https://doi.org/10.1182/blood.V120.21.3989.3989

Published: 2012

Journal Articles

Targeting Bruton's Tyrosine Kinase As a Novel Approach to Inhibit Osteoclast Function in Multiple Myeloma

Homare Eda, MD, PhD, Loredana Santo, MD, Diana D. Cirstea, MD, Samantha Pozzi, MD, Miriam Canavese, PhD, Tyler A. Scullen, BA, Sonia Vallet, MD, Erica Evans, PhD, Juswinder Singh, PhD, Noopur S. Raje, MD

Blood (2011) 118 (21): 2882.

https://doi.org/10.1182/blood.V118.21.2882.2882

Published: 2011

Journal Articles

Increased Sclerostin Secretion in Multiple Myeloma Results in Stimulation of Osteoclastogenesis and Inhibition of Osteoblastogenesis

Homare Eda, MD, PhD, Loredana Santo, MD, Diana D. Cirstea, MD, Samantha Pozzi, MD, Miriam Canavese, PhD, Tyler A. Scullen, BA, Sonia Vallet, MD, Noopur S. Raje, MD

Blood (2011) 118 (21): 1819.

https://doi.org/10.1182/blood.V118.21.1819.1819

Published: 2011

Journal Articles

AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor with Potent Activity Against Aurora Kinase and STAT3 In Combination with Lenalidomide Results In Synergistic Anti-Myeloma Activity

Loredana Santo, MD, Teru Hideshima, MD, PhD, Diana Cirstea, MD, Madhavi L Bandi, PhD, Erik A Nelson, PhD, Hiroshi Ikeda, MD, Sonia Vallet, MD, Samantha Pozzi, MD, Kishan Patel, Gullu Gorgun, PhD, Naoya Mimura, MD, Claire Fabre, MD, Yiguo Hu, PhD, Dharminder Chauhan, PhD, Matthew S Squires, PhD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Noopur Raje, MD

Blood (2010) 116 (21): 2994.

https://doi.org/10.1182/blood.V116.21.2994.2994

Published: 2010

Journal Articles

CYC065, a Potent Derivative of Seliciclib Is Active In Multiple Myeloma In Preclinical Studies

Samantha Pozzi, MD, Diana Cirstea, M.D., Loredana Santo, MD, Doris M Nabikejje, Kishan Patel, Kathryn M Luly, Gaurav Gharti-Chhetry, Sonia Vallet, MD, Homare Eda, MD, PhD, Teru Hideshima, MD, Simon R Green, Kenneth C. Anderson, MD, David T. Scadden, MD, Noopur Raje, MD

Blood (2010) 116 (21): 2999.

https://doi.org/10.1182/blood.V116.21.2999.2999

Published: 2010

Journal Articles

Disruption of DEPTOR/mTORC1/mTORC2 Signaling Cascade Using a Novel Selective mTOR Kinase Inhibitor AZD8055 Results In Growth Arrest and Apoptosis In Multiple Myeloma Cells

Diana Cirstea, Teru Hideshima, Loredana Santo, Samantha Pozzi, Sonia Vallet, Kishan Patel, Gullu Gorgun, Yiguo Hu, Sylvie M Guichard, Anuj Mahindra, Kenneth C. Anderson, Noopur Raje

Blood (2010) 116 (21): 791.

https://doi.org/10.1182/blood.V116.21.791.791

Published: 2010

Journal Articles

Molecular Profiling of Extramedullary and Medullary Plasmacytomas Compared to Multiple Myeloma

Anuj Mahindra, MD, Samir B. Amin, MBBS, Aliyah R. Sohani, MD, Gabriela Motyckova, MD, PhD, Kishan Patel, Sonia Vallet, MD, Samantha Pozzi, Loredana Santo, Diana Cirstea, M.D., Christiana E. Toomey, James S. Michaelson, PhD, Ephraim P. Hochberg, MD, Paola Dal Cin, PhD, Scott J Rodig, Teru Hideshima, Kenneth C. Anderson, Nikhil C. Munshi, MD, Noopur Raje, MD

Blood (2010) 116 (21): 4042.

https://doi.org/10.1182/blood.V116.21.4042.4042

Published: 2010

Journal Articles

Lenalidomide In Combination with the Activin Receptor Type II Murine Fc Protein RAP-011: Preclinical Rationale for a Novel Anti-Myeloma Strategy

Sonia Vallet, MD, Kishan Patel, Diana Cirstea, MD, Katie Luly, Samantha Pozzi, MD, Loredana Santo, MD, Homare Eda, MD, Jasbir Seehra, Anuj Mahindra, MD, David T. Scadden, MD, Noopur Raje, MD

Blood (2010) 116 (21): 4075.

https://doi.org/10.1182/blood.V116.21.4075.4075

Published: 2010

Journal Articles

PI3K/p110δ is a novel therapeutic target in multiple myeloma

Blood (2010) 116 (9): 1460–1468.

https://doi.org/10.1182/blood-2009-06-222943

Published: 2010

Includes: Supplemental data

NARROW

Cox Proportional Hazards Deep Neural Network Identifies Peripheral Blood Complete Remission (PB-CR) to be at Least Equivalent to Morphologic CR in Predicting Outcomes of Patients Treated with Azacitidine - a Prospective Cohort Study By the AGMT

Delineating CDK9- Regulated Molecular Events for the Development of Rationally Derived Multiple Myeloma Treatment Strategies

Combined Targeting of Distinct c-Myc and JunB Transcriptional Programs Inducing Synergistic Anti-Myeloma Activity

Delineating CDK9 Regulated Molecular Events for the Development of Rationally Derived Multiple Myeloma Treatment Strategies

Combined Targeting of Distinct c-Myc and JunB Transcriptional Programs for Multiple Myelioma Therapy

Multiple Myeloma Pathogenesis: The Role of Junb in Bone Marrow Angiogenesis

Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group

The Pathophysiologic Role of JunB in Multiple Myeloma Pathogenesis: Focus on Bone Marrow Angiogenesis

The AP-1 Transcription Factor JunB Promotes Multiple Myeloma (MM) Cell Proliferation, Survival and Drug Resistance in the Bone Marrow Microenvironment

Combinational Therapy of Lenalidomide with Activin A Neutralizing Antibody; Preclinical Rationale for a Novel Anti-Myeloma Strategy

Niche-Based Screening Identifies Novel Small Molecules That Overcome Stromal Effects in Multiple Myeloma

Increased Sclerostin Secretion in Multiple Myeloma Plays a Central Role in Osteolytic Bone Disease

Targeting Bruton's Tyrosine Kinase As a Novel Approach to Inhibit Osteoclast Function in Multiple Myeloma

Increased Sclerostin Secretion in Multiple Myeloma Results in Stimulation of Osteoclastogenesis and Inhibition of Osteoblastogenesis

AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor with Potent Activity Against Aurora Kinase and STAT3 In Combination with Lenalidomide Results In Synergistic Anti-Myeloma Activity

CYC065, a Potent Derivative of Seliciclib Is Active In Multiple Myeloma In Preclinical Studies

Disruption of DEPTOR/mTORC1/mTORC2 Signaling Cascade Using a Novel Selective mTOR Kinase Inhibitor AZD8055 Results In Growth Arrest and Apoptosis In Multiple Myeloma Cells

Molecular Profiling of Extramedullary and Medullary Plasmacytomas Compared to Multiple Myeloma

Lenalidomide In Combination with the Activin Receptor Type II Murine Fc Protein RAP-011: Preclinical Rationale for a Novel Anti-Myeloma Strategy

PI3K/p110δ is a novel therapeutic target in multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only